Co-GP / Platform:Family offices could consider backing a life sciences operator in New York City at the GP level to leverage their expertise and share in the promote.

Co-GP / Platform:Family offices could consider backing a life sciences operator in New York at the GP level to capitalize on the growing demand for specialized facilities.

Co-GP / Platform:Family offices could consider backing a leading life sciences operator in New York City at the GP level to share in the promote and benefit from their expertise and pipeline.

Co-GP / Platform:Family offices could consider backing a life sciences operator in New York at the GP level to capitalize on the growing demand for specialized facilities.

Co-GP / Platform:Family offices could consider backing a leading life sciences operator in New York City at the GP level to share in the promote and benefit from their expertise and pipeline.

Co-GP / Platform:Family offices could consider co-GP or JV equity investments in life sciences operators to capitalize on the tightening market and share in the promote.

Co-GP / Platform:A family office could consider backing a life sciences operator in New York City through co-GP or JV equity to leverage their expertise and pipeline.

Co-GP / Platform:Family offices could consider backing a life sciences operator at the GP level to capitalize on the increasing demand for specialized facilities in New York.

Co-GP / Platform:Family offices could consider backing a leading life sciences operator in New York City at the GP level to share in the promote and benefit from their expertise and pipeline.

Co-GP / Platform:Family offices could consider backing a life sciences operator in New York at the GP level to capitalize on the growing demand for specialized facilities.

Co-GP / Platform:A family office could consider backing a life sciences operator in New York City as a co-GP to capitalize on the sector's growth and share in the promote.

Co-GP / Platform:Family offices could consider backing a life sciences operator in New York at the GP level to capitalize on the growing demand for specialized facilities.

Co-GP / Platform:Family offices could consider backing a life sciences operator at the GP level to leverage their expertise and share in the promote.

Co-GP / Platform:A family office could consider backing a life sciences operator in New York as a co-GP to capitalize on the sector's growth and share in the promote.

Co-GP / Platform:A family office could consider backing a life sciences operator in New York City as a co-GP to capitalize on the sector's growth and share in the promote.

Co-GP / Platform:Family offices could consider backing a life sciences operator at the GP level to capitalize on the growing demand for specialized facilities in New York.

Co-GP / Platform:Family offices could consider co-GP investments in life sciences operators that have a proven track record and access to a strong pipeline of deals in New York.

Co-GP / Platform:Family offices could engage with life sciences operators in New York by providing co-GP or JV equity to capitalize on the sector's growth potential.

Co-GP / Platform:A family office could consider backing a life sciences operator in New York as a co-GP to capitalize on the growing demand for specialized facilities.

Co-GP / Platform:Family offices could consider backing a life sciences operator at the GP level to capitalize on the growing demand for specialized facilities in New York.

Co-GP / Platform:Family offices could consider co-GP or platform capital investments in life sciences operators to capitalize on the growing demand for specialized facilities and the expected increase in tenant activity.

Co-GP / Platform:A family office could consider backing a life sciences operator in New York City through co-GP or JV equity to capitalize on the sector's growth potential.

Co-GP / Platform:Family offices could consider backing a life sciences operator in New York as a co-GP to leverage their expertise and share in the promote.

Co-GP / Platform:A family office could consider backing a life sciences operator in New York as a co-GP to capitalize on the sector's growth and share in the promote.